William Lorenzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William Lorenzi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alcina Juliana Soares Barros
Universidade Federal do Rio Grande do Sul, Brasil
1 shared publication - Ana Helena Paz
Hospital de Clínicas de Porto Alegre
1 shared publication - Antonio Rb de Lima
Internal Medicine Division, Hospital Municipal Getúlio Vargas, Pinheiro Machado 331, Sapucaia do Sul, RS 93210-180, Brazil
1 shared publication Fabiany Da Costa Gonçalves
Experimental Research Center, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos 2350, Porto Alegre, RS, CEP 90035-903, Brazil
1 shared publicationFernanda Visioli
Pathology Department, School of Odontology, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos 2492, Porto Alegre, RS, CEP 90035-007, Brazil
1 shared publication- Gustavo Vasconcelos Alves
Centro Integrado de Pesquisa em Oncologia, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil
1 shared publication
Latest Publications
- 20 May 2017
- Published by Springer Nature in Biotechnology Letters
- Vol. 39 (8) , 1269-1277
Repeated systemic administration of adipose tissue-derived mesenchymal stem cells prevents tracheal obliteration in a murine model of bronchiolitis obliterans
Objective To investigate the effect of adipose tissue-derived mesenchymal stem cell (ASC) administered either systemically or locally in a murine model of bronchiolitis obliterans. Results When compared to controls, systemic treatment with 106 ASCs on D0 and a second dose on D7 significantly prevented tracheal obliteration 28 days after heterotopic tracheal transplantation (median of 94 vs. 16%; P < 0.01). A single dose tended towards less stenosis than controls, but did not reach statistical significance (28 vs. 94%; P = 0.054). On the contrary, repeated local injection was incapable of preventing tracheal obliteration when compared to a single injection or controls (37 vs. 71 vs. 87%). Two intravenous doses also tended to be better than two local injections (16 vs. 37%; P = 0.058), and were better than a single local dose (16 vs. 71%; P < 0.01). Conclusion A second dose of ASC, given systemically after 7 days, reduces luminal obliteration in a heterotopic tracheal transplantation model in mice, suggesting that ASC can be used to prevent obliterative bronchiolitis after lung transplantation.
- 20 May 2017
- Published by Springer Nature in Biotechnology Letters
- Vol. 39 (8) , 1269-1277
Repeated systemic administration of adipose tissue-derived mesenchymal stem cells prevents tracheal obliteration in a murine model of bronchiolitis obliterans
Objective To investigate the effect of adipose tissue-derived mesenchymal stem cell (ASC) administered either systemically or locally in a murine model of bronchiolitis obliterans. Results When compared to controls, systemic treatment with 106 ASCs on D0 and a second dose on D7 significantly prevented tracheal obliteration 28 days after heterotopic tracheal transplantation (median of 94 vs. 16%; P < 0.01). A single dose tended towards less stenosis than controls, but did not reach statistical significance (28 vs. 94%; P = 0.054). On the contrary, repeated local injection was incapable of preventing tracheal obliteration when compared to a single injection or controls (37 vs. 71 vs. 87%). Two intravenous doses also tended to be better than two local injections (16 vs. 37%; P = 0.058), and were better than a single local dose (16 vs. 71%; P < 0.01). Conclusion A second dose of ASC, given systemically after 7 days, reduces luminal obliteration in a heterotopic tracheal transplantation model in mice, suggesting that ASC can be used to prevent obliterative bronchiolitis after lung transplantation.
- Open Access
- 3 October 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 326
Mood disorder as a manifestation of primary hypoparathyroidism: a case report
Primary hypoparathyroidism is a rare condition caused by parathyroid hormone deficiency and characterized by hypocalcemia. The clinical manifestations of primary hypoparathyroidism include tetany, seizures, paresthesias, dementia, and parkinsonism. Psychiatric manifestations such as mood disorders are unusual and may constitute a major diagnostic challenge, especially if the typical manifestations caused by hypocalcemia are absent.
- 3 October 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 326
Open AccessMood disorder as a manifestation of primary hypoparathyroidism: a case report
Primary hypoparathyroidism is a rare condition caused by parathyroid hormone deficiency and characterized by hypocalcemia. The clinical manifestations of primary hypoparathyroidism include tetany, seizures, paresthesias, dementia, and parkinsonism. Psychiatric manifestations such as mood disorders are unusual and may constitute a major diagnostic challenge, especially if the typical manifestations caused by hypocalcemia are absent.